Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Cripto-1 as a Biomarker for Cardiac Ischemia

Posted Jun 30 2008 5:00pm

Description of Invention:
Ischemic heart disease is a major cause of human cardiac morbidity and mortality, affecting over 14 million people in the United States alone. Current detection of cardiac ischemia relies upon identification of electrocardiographic anomalies and the release of cardiac markers from the damaged myocardial tissue. Unfortunately, patients with acute myocardial infarction are often insensitive to these tests during the early phases of intervention and as a result more markers for cardiac ischemic disease are needed.

This technology describes Cripto-1 as a biomarker for infarcted cardiac tissues. Cripto-1 is a member of the epidermal growth factor (EGF)-related proteins and is currently thought to play an important role in several cancers. The present invention shows that Cripto-1 is overexpressed in infarcted myocardial tissue, and not expressed or weakly expressed in non-infarct related heart disease tissues and normal tissues. Furthermore, the overexpression of Cripto-1 correlates with the hypoxia-inducible factor-1-alpha indicating specificity to ischemic heart tissue. The expression of Cripto-1 has also been shown to be highly expressed in stem cells, which may have an important role in the repair of damaged myocardial tissue. Thus, this technology could represent a new biomarker for the diagnosis of myocardial infarction as well as a surrogate biomarker to monitor the healing process including regenerative stem cell activity of the infarcted myocardial tissue.

Applications:
  • Diagnostic tool for the detection of myocardial infarction.
  • Method to monitor stem cell activity in damaged myocardial tissue.


Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Luigi Strizzi (NCI)
Caterina Bianco (NCI)
David S Salomon (NCI)


Patent Status:
HHS, Reference No. E-049-2008/0
PCT, Application No. PCT/US09/40971 filed 17 Apr 2009


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The National Cancer Institute Mammary Biology and Tumorigenesis Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Cripto-1 as a biomarker for cardiac ischemia. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Internal Medicine
Internal Medicine - Diagnostics



For Additional Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220


Ref No: 1776

Updated: 07/2008

Post a comment
Write a comment: